Receptor specific transepithelial transport of immunogens

(19)

(11)

EP 1 658 772 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 A2)

(48)	Corrigendum issued on:
	10.01.2007 Bulletin 2007/02

(43)	Date of publication:
	24.05.2006 Bulletin 2006/21

(21)	Application number: 05112065.7

(22)	Date of filing: 17.01.1996

(51)

International Patent Classification (IPC):

A01N 63/00^(2006.01)
A61K 39/00^(2006.01)

A61K 39/385^(2006.01)
A61K 47/48^(2006.01)

(84)	Designated Contracting States:
	AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

(30)

Priority:

17.01.1995 US 374159
29.12.1995 US 578171

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	03004479.6 / 1323346
	96903522.9 / 0805628

(71)	Applicants:
	THE BRIGHAM AND WOMEN'S HOSPITAL, INC. Boston, MA 02115 (US) BRANDEIS UNIVERSITY Waltham, MA 02254 (US)

(72)	Inventors:
	Blumberg, Richard S. Chestnut Hill, Massachusetts 02167 (US) Simister, Neil E. Wellesley, Massachusetts 02482 (US) Lencer, Wayne I. Jamaica Plain, Massachusetts 02130 (US)

(74)	Representative: Cowley, Catherine Mary et al
	Venner Shipley LLP, 20 Little Britain London EC1A 7DH London EC1A 7DH (GB)


	Remarks:
	This application was filed on 13 - 12 - 2005 as a divisional application to the application mentioned under INID code 62.

(54)	Receptor specific transepithelial transport of immunogens

(57) Methods and products for modulating an immune response are provided. Pharmaceutical preparations contain a conjugate of an antigen and an FcRn binding partner. The conjugates are administered to mammals in effective amounts to modulate the immune system by stimulating the immune response against the antigen or tolerizing the immune system to the antigen. The antigen may be characteristic of a pathogen, of an autoimmune disease, of an allergen or of a tumor.